Predicted Number of Peanut-allergic Patients Needed to Treat with Epicutaneous Immunotherapy (EPIT) to Prevent One Allergic Reaction: A Novel Approach to Assessing Relevance

Authors

• Benjamin C. Remington, University of Nebraska-LincolnFollow
• Stef J. Koppelman, University of Nebraska-LincolnFollow
• Todd D. Green, DBV Technologies, UPMC Children’s Hospital of Pittsburgh
• Gideon Lack, King’s College London, Guy’s and St. Thomas’ NHS Foundation Trust
• Graham Roberts, University of Southampton, St. Mary’s Hospital
• Dianne E. Campbell, DBV Technologies, Children’s Hospital at Westmead

ORCID IDs

Remington https://orcid.org/0000-0001-5450-8334

Koppelman 0000-0001-7995-1754

Green 0000-0002-2586-3625

Lack 0000-0001-7350-4021

Roberts 0000-0003-2252-1248

Campbell 0000-0002-0907-6963

Document Type

Article

Date of this Version

2021

Citation

Allergy (2021) 76(10): 3,223-3,226

doi: 10.1111/all.14973

Comments

Open access

Abstract

Letter to the editor about the predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction, including a novel approach to assessing relevance.